The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

• Status: Recruiting
• Trial end date: 2022-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sacsh

Criteria

Inclusion Criteria:

• Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.

• At least 18 years of age.

• Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.

• Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.

• A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.

• All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.

• Patients will require a rating of 1 (mild) for bulbar conjunctival injection.

Exclusion Criteria:

• Conjunctivitis greater than 72 hours after initial ocular symptoms

• Corneal ulcer, endophthalmitis, or any other confounding infection of the eye

• Patients taking topical anti-inflammatory medications on a chronic basis

• Known steroid glaucoma responders

• Active herpes ocular infection

• Pregnant women

• Known allergy to chlorhexidine